Aileron Therapeutics, Inc. (NASDAQ:ALRN) Sees Significant Decrease in Short Interest

Aileron Therapeutics, Inc. (NASDAQ:ALRN - Get Free Report) saw a large decrease in short interest in November. As of November 15th, there was short interest totalling 180,700 shares, a decrease of 22.5% from the October 31st total of 233,300 shares. Currently, 0.9% of the company's stock are sold short. Based on an average trading volume of 78,900 shares, the days-to-cover ratio is currently 2.3 days.

Aileron Therapeutics Trading Up 4.4 %

NASDAQ:ALRN traded up $0.12 during mid-day trading on Friday, hitting $2.86. 14,804 shares of the company's stock traded hands, compared to its average volume of 73,709. The firm has a 50 day moving average of $3.46 and a two-hundred day moving average of $3.07. The firm has a market capitalization of $61.98 million, a price-to-earnings ratio of -0.88 and a beta of 2.35. Aileron Therapeutics has a 12 month low of $1.61 and a 12 month high of $7.42.

Institutional Investors Weigh In On Aileron Therapeutics

Several large investors have recently modified their holdings of the stock. University of Texas Texas AM Investment Management Co. bought a new stake in Aileron Therapeutics during the second quarter worth about $4,925,000. Nantahala Capital Management LLC boosted its holdings in shares of Aileron Therapeutics by 82.1% in the 2nd quarter. Nantahala Capital Management LLC now owns 464,367 shares of the company's stock worth $1,286,000 after acquiring an additional 209,367 shares in the last quarter. Geode Capital Management LLC grew its position in Aileron Therapeutics by 34.8% during the 3rd quarter. Geode Capital Management LLC now owns 229,817 shares of the company's stock worth $814,000 after acquiring an additional 59,370 shares during the last quarter. Sigma Planning Corp increased its holdings in Aileron Therapeutics by 68.3% during the 3rd quarter. Sigma Planning Corp now owns 212,410 shares of the company's stock valued at $752,000 after purchasing an additional 86,185 shares in the last quarter. Finally, Warberg Asset Management LLC bought a new position in Aileron Therapeutics in the 2nd quarter valued at $86,000. 90.89% of the stock is currently owned by institutional investors.

About Aileron Therapeutics

Aileron Therapeutics, Inc, a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 1b clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.